VIRX — Viracta Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Viracta Therapeutics Announces Interim Data From Phase 1B/2 Clinical Trial Of Nana-Val
Brief: Viracta Therapeutics Q3 EPS USD -0.33
Brief: Viracta Therapeutics Q2 Net Income USD -12.5 Mln
Viracta Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Viracta Therapeutics Appoints Darrel Cohen As Chief Medical Officer
Viracta Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Ashland, McKesson, Snowflake
Brief: Viracta Therapeutics Pivotal Trial Achieves Efficacy Threshold For Expansion In Ebv-Positive Peripheral T-Cell Lymphoma
Brief: Viracta Therapeutics Reports First Quarter 2023 Financial Results And Provides Clinical Program Updates
Viracta Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Viracta Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Viracta Therapeutics Announces Departure Of Chief Medical Officer
Viracta Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Viracta Therapeutics Reports Q4 And Full Year 2022 Financial Results And Provides A Corporate Update
Viracta Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Viracta Therapeutics Announces Orphan Drug Designation Granted By The European Commission To Nana-Val For The Treatment Of Diffuse Large B-Cell Lymphoma
Brief: Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
Brief: Viracta Therapeutics Announces Preliminary Dose-Ranging Data Of Nana-Val In Advanced Epstein-Barr Virus-Positive Solid Tumors
Brief: Viracta Therapeutics Announces New Employment Inducement Grant